Abstract

IntroductionThe Canadian Sentinel Practitioner Surveillance Network reports vaccine effectiveness (VE) for the 2018/19 influenza A(H3N2) epidemic.AimTo explain a paradoxical signal of increased clade 3C.3a risk among 35–54-year-old vaccinees, we hypothesise childhood immunological imprinting and a cohort effect following the 1968 influenza A(H3N2) pandemic.MethodsWe assessed VE by test-negative design for influenza A(H3N2) overall and for co-circulating clades 3C.2a1b and 3C.3a. VE variation by age in 2018/19 was compared with amino acid variation in the haemagglutinin glycoprotein by year since 1968.ResultsInfluenza A(H3N2) VE was 17% (95% CI: −13 to 39) overall: 27% (95% CI: −7 to 50) for 3C.2a1b and −32% (95% CI: −119 to 21) for 3C.3a. Among 20–64-year-olds, VE was −7% (95% CI: −56 to 26): 6% (95% CI: −49 to 41) for 3C.2a1b and −96% (95% CI: −277 to −2) for 3C.3a. Clade 3C.3a VE showed a pronounced negative dip among 35–54-year-olds in whom the odds of medically attended illness were > 4-fold increased for vaccinated vs unvaccinated participants (p < 0.005). This age group was primed in childhood to influenza A(H3N2) viruses that for two decades following the 1968 pandemic bore a serine at haemagglutinin position 159, in common with contemporary 3C.3a viruses but mismatched to 3C.2a vaccine strains instead bearing tyrosine.DiscussionImprinting by the first childhood influenza infection is known to confer long-lasting immunity focused toward priming epitopes. Our findings suggest vaccine mismatch may negatively interact with imprinted immunity. The immunological mechanisms for imprint-regulated effect of vaccine (I-REV) warrant investigation.

Highlights

  • IntroductionSurveillance Network reports vaccine effectiveness (VE) for the 2018/19 influenza A(H3N2) epidemic

  • The Canadian Sentinel PractitionerSurveillance Network reports vaccine effectiveness (VE) for the 2018/19 influenza A(H3N2) epidemic

  • influenzalike illness (ILI) was estimated by test-negative design whereby the odds of vaccination in influenza test-positive cases were compared with influenza test-negative controls via the odds ratio (OR) [1,21]

Read more

Summary

Introduction

Surveillance Network reports vaccine effectiveness (VE) for the 2018/19 influenza A(H3N2) epidemic. In the interim analysis for the 2018/19 influenza season, the Canadian Sentinel Practitioner Surveillance. Network (SPSN) reported substantial vaccine effectiveness (VE) of 72% (95% confidence interval (CI): 60 to. 81) for the primary influenza A(H1N1)pdm epidemic that peaked in late December and early January [1]. The. SPSN reported a prominent shift in the age distribution of influenza A(H1N1)pdm cases to include more children younger than 10 years. It was postulated that this reflected an immunological cohort effect following the 2009 influenza A(H1N1)pdm pandemic [2]. Thereafter, Canada experienced a secondary influenza A wave due to H3N2 subtype viruses that peaked unusually late, in March 2019 [3]. Vaccine effectiveness against influenza A(H3N2) viruses overall and by age and genetic subgroup, Canadian Sentinel.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call